Showing 11 - 20 of 86
This article examines the effect that different specifications of the time trade-off (TTO) valuation task may have on values for EQ-5D-5L health states. The new variants of the TTO, namely lead-time TTO and lag-time TTO, along with the classic approach to TTO were compared using two durations...
Persistent link: https://www.econbiz.de/10010993940
<Emphasis Type="Bold">Background: A common way of describing UK National Institute for Health and Clinical Excellence (NICE) decisions is to distinguish between cases where NICE recommended use of a healthcare technology by all relevant patients (‘yes’); those where it did not recommend use (‘no’); and those...</emphasis>
Persistent link: https://www.econbiz.de/10011001610
ABSTRACT This paper describes the development of a methodology for the case‐mix adjustment of patient‐reported outcome measures (PROMs) data permitting the comparison of outcomes between providers on a like‐for‐like basis. Statistical models that take account of provider‐specific...
Persistent link: https://www.econbiz.de/10011160893
Background: The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant. Observing NICE decisions and the evidence considered in...
Persistent link: https://www.econbiz.de/10011133797
The English Department of Health has introduced routine collection of patient-reported health outcome data for selected surgical procedures (hip and knee replacement, hernia repair, varicose vein surgery) to facilitate patient choice and increase provider accountability. The EQ-5D has been...
Persistent link: https://www.econbiz.de/10010533833
Accounting for variation in the quality of care is a major challenge for the assessment of hospital cost performance. Because data on patients’ health improvement are generally not available, existing studies have resorted to inherently incomplete outcome measures such as mortality or...
Persistent link: https://www.econbiz.de/10010533834
The UK Government is proposing a novel form of price regulation for branded medicines, which it has dubbed ‘value-based pricing’ (VBP). The specifics of how VBP will work are unclear. We provide an account of the possible means by which VBP of medicines might be operationalized, and a...
Persistent link: https://www.econbiz.de/10010634490
Granger causality is tested for to examine the exogeneity of GDP which is assumed in previous research on the determinants of aggregate health care spending. In theory, the causal relationship between these variables could be in either or both directions. For some of the 20 OECD countries tested...
Persistent link: https://www.econbiz.de/10009195933
Persistent link: https://www.econbiz.de/10010826471
Persistent link: https://www.econbiz.de/10012632680